Should Serum Protein Electrophoresis Be a Surrogate for Liver Biopsy in Some Cases of Alpha_1 Antitrypsin Deficiency?

Newton Key Hokama,1 Marcelo Padovani de Toledo Moraes,2 Paula de Oliveira Montandon Hokama,1 and Fernando Gomes Romeiro3

1Internal Medicine Department, Hematology Division, Botucatu Medical School, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
2Pathology Department, Botucatu Medical School, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
3Internal Medicine Department, Gastroenterology Division, Botucatu Medical School, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil

Correspondence should be addressed to Fernando Gomes Romeiro; fgromeiro@gmail.com

Received 3 April 2017; Revised 5 August 2017; Accepted 23 August 2017; Published 28 September 2017

1. Introduction

Alpha_1 antitrypsin deficiency (AATD) was first diagnosed in 1963, when Carl-Bertil Laurell and Sten Eriksson noticed that the α1-protein band in serum protein electrophoresis was absent in five patients [1]. They pointed out two relevant facts: the use of serum protein electrophoresis to make the diagnosis and the role of case reports when assessing diseases that are usually underdiagnosed. Despite all the progress achieved after this initial description, the disease is still unrecognized until the occurrence of complications that bring the patients to specialists [2, 3].

The enzyme alpha_1 antitrypsin is a serine protease inhibitor capable of neutralizing the proteolysis caused by the neutrophil elastase released from the azurophilic granules of these cells [2]. AATD has been included in the group of diseases caused by misfolding and intracellular polymerization of serpin superfamily members [1, 4]. Patients stricken by serpinopathies suffer one of two distinct pathophysiological patterns: loss-of-function deficiencies, such as what occurs in emphysema, or a toxic effect due to accumulation of abnormal proteins, such as in cirrhosis [2].

The disease is more common among Caucasian people, accounting for 1.1% of adult liver transplants in the UK [3], but it is uncommon in Asian countries [2]. The mutation found in patients with AATD leads to protein retention within hepatocytes, which in turn causes liver damage [4]. The lack of alpha_1 antitrypsin is associated with panlobular basal emphysema, which is the primary cause that leads to the diagnosis and can be found in 1-2% of patients with chronic obstructive pulmonary disease (COPD) [4]. However, it may be difficult to establish the diagnosis when the patients do not present with respiratory symptoms, because the protein retention into the liver is often asymptomatic. Therefore, in this report, we present a patient with AATD with a typical pattern observed in serum protein electrophoresis as a surrogate for liver biopsy in alpha_1 antitrypsin deficiency is discussed.
Figure 1: Serum protein electrophoresis investigation with reduced alpha₁ globulin band (arrow, column 18).

Figure 2: Liver biopsy showing nodules and fibrous septa associated with effacement of lobular architecture in Hematoxylin-Eosin staining.

Figure 3: Liver biopsy showing nodules and fibrous septa associated with effacement of lobular architecture in Masson’s trichrome stain.

Figure 4: Liver biopsy showing the periportal localization of periodic acid-Schiff positive inclusion bodies, confirming the diagnosis of alpha₁ antitrypsin deficiency.

2. Case Report

An asymptomatic 44-year-old woman with ascites and other portal hypertension findings in a recent ultrasonography came to medical consultation. Serological tests for viral hepatitis were negative and she was not an alcohol consumer.

Serum protein electrophoresis revealed reduced alpha₁ globulin band (Figure 1).

Liver biopsy showed nodules and fibrous septa with effacement of lobular architecture in Hematoxylin-Eosin (Figure 2) and Masson’s trichrome (Figure 3) stains. Periportal localization of periodic acid-Schiff positive inclusion bodies was observed (Figure 4), confirming the diagnosis of alpha₁ antitrypsin deficiency. Her liver biopsy was uneventful, but before any additional exams such as genetic analysis, she passed away due to septic shock.

3. Discussion

In spite of the success in establishing the diagnosis when patients with AATD are submitted to liver transplantation, only few cases receive this diagnosis [5–7]. Most physicians do not test patients for AATD, spending more than five years until the disease is recognized [2]. Since only 10% of patients or less are properly diagnosed, AATD is still an uncommon cause of liver disease submitted to liver transplantation [8]. After AATD suspicion, the diagnosis usually begins by testing the serum levels of alpha₁ antitrypsin in patients with established risk factors, but sometimes the disease is only revealed after liver biopsy [9].

The associated findings are COPD, emphysema or asthma with incompletely reversible airflow obstruction, bronchietasis or chronic liver disease without a clear etiology (such as cryptogenic cirrhosis), persistent airway obstruction, necrotizing panniculitis, c-ANCA-positive vasculitis, family history of AATD, COPD, or liver disease (which could be attributed to AATD), and people at high risk for AATD [2]. Other reasons could be considered from genetic tests suggesting a high risk for AATD.

Liver disease caused by AATD occurs in patients older than those who have a pulmonary disease, raising the hypothesis that when they do not develop emphysema in younger ages it could be a risk factor for liver disease in middle age [2]. In this setting, the absence of pulmonary findings can be a barrier to the diagnosis, leading to cryptogenic cirrhosis and liver cancer. Additionally, when patients have infections or any other inflammatory conditions, serum lab tests can be unreliable, because alpha₁ antitrypsin levels can increase in the presence of inflammation [10]. Once the patient developed liver cirrhosis, some complications such as ascites, thrombocytopenia, and/or prothrombin time alterations make it difficult to obtain adequate liver samples through percutaneous liver biopsy, sometimes precluding the diagnosis of AATD. For these patients, serum protein electrophoresis, genetic tests, and transjugular liver biopsy
could be performed in order to search for the initial liver disease.

Most cases of liver disease are associated with homozygosity for the Z mutant allele, also called PiZZ, in which the anomalous protein folds improperly inside hepatocytes. Consequently, approximately 85% of the molecules are retained into these cells instead of being secreted [11]. As a result, the low alpha\textsubscript{1} antitrypsin serum level can be easily detected by serum protein electrophoresis [11].

Therefore, when a typical pattern is observed in serum protein electrophoresis, it can be a relevant clue to suggest the presence of AATD. However, it could never be enough to establish the diagnosis without further exams, such as genetic tests. Worth mentioning is that when the pattern observed is not so specific as shown in this report, the disease could be never ruled out, and genetic tests and/or liver biopsies should be carried out. As AATD is still a cause for high mortality rates associated with liver and lung complications, the proper diagnosis can save lots of patients stricken by this disease [12,13].

In conclusion, we suggest that every patient with cryptogenic cirrhosis should be submitted to specific tests considering AATD, with special attention to serum protein electrophoresis. If a typical pattern is observed in this exam, the diagnosis of AATD must be suspected, leading to worthy indications of additional exams such as genetic tests, perhaps avoiding the need of invasive exams such as liver biopsy.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors would like to acknowledge the financial support received from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Capes, Pró-Reitoria de Pesquisa, PROPe/UNESP, and São Paulo Research Foundation, FAPESP Grant no. 2016/07117-9.

References

[1] C.-B. E. Laurell and S. Eriksson, “The electrophoretic α\textsubscript{1}-globulin pattern of serum in α\textsubscript{1}-antitrypsin deficiency,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 15, no. 2, pp. 132–140, 1963.

[2] U. Hatipoğlu and J. K. Stoller, “α\textsubscript{1}-antitrypsin deficiency,” Clinics in Chest Medicine, vol. 37, no. 3, pp. 487–504, 2016.

[3] B. Mostafavi, S. Diaz, H. A. Tanash, and E. Piitulainen, “Liver function in α\textsubscript{1}-antitrypsin deficient individuals at 37 to 40 years of age,” Medicine (United States), vol. 96, no. 12, Article ID e6180, 2017.

[4] D. A. Lomas, J. R. Hurst, and B. Goopu, “Update on α\textsubscript{1}-antitrypsin deficiency: New therapies,” Journal of Hepatology, vol. 65, no. 2, pp. 413–424, 2016.

[5] V. C. Clark, “Liver transplantation in α\textsubscript{1}-antitrypsin deficiency,” Clinics in Liver Disease, vol. 21, no. 2, pp. 355–365, 2017.

[6] A. Bakula, J. Pawłowska, O. Niewiadomska et al., “Liver transplantation in polish children with α\textsubscript{1}-antitrypsin deficiency: a single-center experience,” Transplantation Proceedings, vol. 48, no. 10, pp. 3323–3327, 2016.

[7] M. P. Henao and T. J. Craig, “Understanding α\textsubscript{1} antitrypsin deficiency: a review with an allergist’s outlook,” Allergy and Asthma Proceedings, vol. 38, no. 2, pp. 98–107, 2017.

[8] A. Akdur, M. Kirnap, E. H. A. Soy et al., “Unusual indications for a liver transplant: a single-center experience,” Experimental and Clinical Transplantation, vol. 15, pp. 128–132, 2017.

[9] P. Y. Kwo, S. M. Cohen, and J. K. Lim, “ACG clinical guideline: evaluation of abnormal liver chemistries,” The American Journal of Gastroenterology, vol. 112, no. 1, pp. 18–35, 2016.

[10] S. Santangelo, S. Scarlata, M. L. Poeta, A. J. Bialas, G. Paone, and R. A. Incalzi, “Alpha-1 antitrypsin deficiency: current perspective from genetics to diagnosis and therapeutic approaches,” Current medicinal chemistry, vol. 24, no. 1, pp. 65–90, 2017.

[11] K. S. Blomenkamp and J. H. Teckman, “Semiquantitation of Monomer And Polymer Alpha-1 Antitrypsin by Centrifugal Separation And Assay by Western Blot of Soluble and Insoluble Components,” in Alpha-1 Antitrypsin Deficiency, vol. 1639 of Methods in Molecular Biology, pp. 227–234, Springer New York, New York, NY, 2017.

[12] H. A. Tanash, M. Ekström, P. Wagner, and E. Piitulainen, “Cause-specific mortality in individuals with severe α\textsubscript{1} antitrypsin deficiency in comparison with the general population in Sweden,” International Journal of COPD, vol. 11, no. 1, pp. 1663–1669, 2016.

[13] B. Norton, J. Denson, C. Briggs, M. Bowles, D. Stell, and S. Aroori, “Delayed diagnosis of alpha-1-antitrypsin deficiency following post-hepatectomy liver failure: a case report,” World Journal of Gastroenterology, vol. 22, no. 11, pp. 3289–3295, 2016.